Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 2.52 | 2.06 | 0.72 | 2.36 | 2.19 | 0.34 | 0.38 | 0.78 | 0.70 | 1.96 | 3.40 | 3.85 | 1.17 | 1.44 | 0.77 | 1.74 | 1.36 | 1.04 | 2.00 | 2.40 | 7.75 |
| — | +498.6% | +91.5% | +204.2% | +212.2% | -82.4% | -88.9% | -79.8% | -40.1% | +35.9% | +343.0% | +120.6% | -13.9% | +38.7% | -61.5% | -27.3% | -82.5% | -80.8% | -71.7% | -68.2% | +74.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -145.7% | -12.5% | -20.2% | -64.6% | -40.6% | -34.0% | -30.5% | -23.3% | -20.7% | -24.4% | -20.1% | -25.4% | -26.7% | -15.1% | -12.0% | -11.2% | -11.7% | -10.0% | -6.9% | -7.6% | -6.2% |
| — | +63.2% | +33.6% | -177.2% | -95.5% | -39.5% | -51.5% | +8.2% | +22.4% | -61.5% | -67.8% | -127.4% | -128.3% | -51.1% | -72.6% | -46.8% | -88.3% | -152.4% | -107.6% | -38.0% | -4.6% | |
| ROA | -98.3% | -10.6% | -15.1% | -32.2% | -24.9% | -24.0% | -22.9% | -17.5% | -15.3% | -18.4% | -15.6% | -19.7% | -21.9% | -13.0% | -10.3% | -9.8% | -10.6% | -9.3% | -6.6% | -7.3% | -6.0% |
| — | +55.8% | +34.0% | -84.3% | -62.1% | -30.1% | -46.4% | +11.0% | +29.9% | -41.5% | -51.4% | -99.8% | -105.6% | -40.5% | -56.5% | -34.9% | -77.9% | -143.5% | -102.0% | -35.7% | -7.4% | |
| ROIC | -122.0% | -10.9% | -20.5% | -85.2% | -38.8% | -28.8% | -26.0% | -19.4% | -16.7% | -19.0% | -16.1% | -21.0% | -23.3% | -14.8% | -11.7% | -10.3% | -11.1% | -11.6% | -20.0% | -5024.5% | — |
| — | +62.0% | +21.3% | -338.8% | -132.0% | -51.6% | -61.3% | +7.5% | +28.2% | -27.9% | -37.7% | -103.9% | -109.9% | -27.8% | +41.5% | +99.8% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.07 | 0.03 | 0.20 | 0.10 | 0.25 | 0.11 | 0.09 | 0.07 | 0.11 | 0.10 | 0.09 | 0.06 | 0.04 | 0.04 | 0.04 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | -71.6% | -69.5% | +130.4% | +35.0% | +129.1% | +10.1% | -3.8% | +26.7% | +145.2% | +137.0% | +129.0% | +146.7% | +1216.1% | +1351.2% | +1836.8% | +1160.2% | +155.3% | +430.8% | — | -92.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.07 | 9.71 | 7.21 | 2.07 | 2.40 | 4.52 | 5.47 | 7.26 | 4.82 | 4.39 | 5.21 | 5.24 | 5.66 | 12.49 | 10.62 | 9.57 | 11.52 | 13.23 | 21.00 | 24.00 | 31.15 |
| — | +114.6% | +31.9% | -71.6% | -50.2% | +3.1% | +5.0% | +38.6% | -14.9% | -64.9% | -51.0% | -45.2% | -50.8% | -5.5% | -49.4% | -60.1% | -63.0% | -55.1% | -31.4% | -65.9% | -14.6% | |
| Quick Ratio | 2.07 | 9.71 | 7.21 | 2.07 | 2.40 | 4.52 | 5.47 | 7.26 | 4.82 | 4.39 | 5.21 | 5.24 | 5.66 | 12.49 | 10.62 | 9.57 | 11.52 | 13.23 | 21.00 | 24.00 | 31.15 |
| — | +114.6% | +31.9% | -71.6% | -50.2% | +3.1% | +5.0% | +38.6% | -14.9% | -64.9% | -51.0% | -45.2% | -50.8% | -5.5% | -49.4% | -60.1% | -63.0% | -55.1% | -31.4% | -65.9% | -14.6% | |
| Interest Coverage | -62.48 | -63.27 | -53.16 | -58.66 | -53.27 | -63.07 | -74.75 | -67.30 | -67.85 | -90.84 | -82.33 | -108.57 | -129.41 | -90.83 | -76.99 | — | -17659.00 | -16459.00 | -8176.67 | -9485.33 | -6144.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALXO stock.
ALX Oncology Holdings Inc.'s current P/E is -0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ALX Oncology Holdings Inc.'s business trajectory between earnings reports.